gsk2982772
Small moleculeexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2015 (NCT02302404)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)[C@@H](NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2ccccc21- Mol. weight
- 377.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4071864 ↗
Also known as
- gsk2982772
- gsk2982772
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04316585 | Phase 1 | Sep 22, 2020 | GlaxoSmithKline |
| NCT03649412 | Phase 1 | Sep 25, 2018 | GlaxoSmithKline, Quotient |
| NCT03590613 | Phase 1 | Jul 19, 2018 | GlaxoSmithKline |
| NCT03305419 | Phase 1 | Oct 11, 2017 | GlaxoSmithKline |
| NCT03266172 | Phase 1 | Sep 27, 2017 | GlaxoSmithKline, Quotient |
| NCT02903966 | Phase 2 | Nov 1, 2016 | GlaxoSmithKline |
| NCT02858492 | Phase 2 | Oct 1, 2016 | GlaxoSmithKline |
| NCT02776033 | Phase 2 | Aug 30, 2016 | GlaxoSmithKline |
| NCT02302404 | Phase 1 | Jan 6, 2015 | GlaxoSmithKline, University of Cambridge |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 9 | 9 | 2 | 2015 |
| Quotient | For profit | 2 | 0 | 1 | 2017 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1